Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecozotan SR in mild to moderate Alzheimer's Disease
NCT00151398Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of lecozotan in Alzheimer's disease (AD) (4 arms), sponsored by Pfizer. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 40 weeks and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change at 40 weeks. Started Oct 2005; status: completed.
02
Drugs
lecozotan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00151398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151398.